The ability to detect and target complex multi-omics signatures is the basis for personalized medicine. But typical AI cannot discover effective biomarkers from real-life clinical trial data. Prism AI’s cloud computing platform provides a powerful and novel AI approach expertly designed for biomarker discovery, companion diagnostics (CDx), and drug target identification from raw, real-time clinical trial data. We specialize in extracting novel insights from label-free (unsupervised), small patient cohort sizes and multi-omics data, ensuring data harmonization and systemic batch effect corrections across diverse sites, collection protocols, demographic variables, and measurement platforms. Our patented technology, based on quantum mechanics, has produced multiple novel oncology biomarkers that have been clinically proven to be the most accurate and precise in peer-reviewed publications.